Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort.

ABSTRACT:

Background & aims

The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients treated with tenofovir disoproxil fumarate (TDF) and entecavir (ETV) using a nationwide cohort in South Korea.

Method

We analyzed 40,404 patients with CHB treated with either TDF (n = 23,779) or ETV (n = 16,625). The risk of osteoporosis and osteoporotic fractures was evaluated using Cox proportional hazards models, incidence rate ratios (IRRs), and Kaplan-Meier survival analysis. To adjust for baseline differences, inverse probability of treatment weighting was applied.

Result

Over a mean follow-up of 50.8 months, osteoporosis o

SUBMITTER: Shin YE 

PROVIDER: S-EPMC12355098 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature